AstraZeneca(US:AZN) 智通财经网·2025-08-15 13:02Core Insights - AstraZeneca has launched its home-use flu vaccine, FluMist Home, amid ongoing debates in the U.S. regarding vaccine accessibility [1] - The product is available for online ordering and is FDA-approved for individuals aged 2 and above [1][2] - AstraZeneca's stock has risen 22% this year, outperforming the S&P 500, driven by strong revenue from its oncology drug portfolio [1] Product Details - FluMist Home allows insured customers to pay only $8.99 for shipping and handling, while uninsured customers can pay approximately $70 [2] - The vaccine aims to increase vaccination rates, which have declined since the COVID-19 pandemic, with only 46% of U.S. adults vaccinated last flu season [2][3] - The product will be shipped in refrigerated containers, and customers will receive alerts if the temperature is not maintained [3] Market Context - The launch coincides with a turbulent period for U.S. vaccine policy, including the dismissal of influential vaccine committee members by the Health and Human Services Secretary [2] - AstraZeneca has committed to investing approximately $50 billion in the U.S. market for manufacturing and R&D projects by 2030 [4] - The company operates one of its manufacturing sites in Philadelphia, which serves 20 countries [4]